Drug
F2c22c Dl001z
F2c22c Dl001z: highest development phase Phase 1/2, developed by GlaxoSmithKline. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1/2
- Developer
- GlaxoSmithKline
Trials
| Drug | Phase | Indication |
|---|---|---|
| F2C22C/DL001Z NCT05823974 | Phase 1/2 | Influenza, Human |
Latest
No recent events.
Follow F2c22c Dl001z on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.